Zymeworks Announces Participation in Upcoming Investor Conferences
2023年8月1日 - 9:30PM
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology
company developing novel, multifunctional biotherapeutics, today
announced that management will participate in the following
upcoming investor conferences:
- Citi's 2023 18th Annual BioPharma Conference: Zymeworks’
management will participate in one-on-one meetings and a co-panel
discussion on September 6th at 10:30 am Eastern Time (ET) in
Boston, MA.
- Wells Fargo Healthcare Conference: Zymeworks’ management will
participate in one-on-one meetings and a fireside chat on September
7th – 8th in Boston, MA.
- H.C. Wainwright 25th Annual Global Investment Conference:
Zymeworks’ management will participate in one-on-one meetings and
present on September 11th in New York, NY.
- Morgan Stanley’s 21st Annual Global Healthcare Conference:
Zymeworks’ management will participate in one-on-one meetings and a
fireside chat on September 12th in New York, NY.
- Cantor Global Healthcare Conference: Zymeworks’ management will
participate in one-on-one meetings and a fireside chat on September
27th in New York, NY.
All presentations and webcasts will be available on Zymeworks’
website at http://ir.zymeworks.com/events-and-presentations.
About Zymeworks Inc.
Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company
committed to the discovery, development, and commercialization of
novel, multifunctional biotherapeutics. Zymeworks' mission is to
make a meaningful difference for people impacted by
difficult-to-treat cancers and other serious diseases. Zymeworks'
complementary therapeutic platforms and fully integrated drug
development engine provide the flexibility and compatibility to
precisely engineer and develop highly differentiated antibody-based
therapeutic candidates. Zymeworks engineered and developed
zanidatamab, a HER2-targeted bispecific antibody using Zymeworks'
proprietary Azymetric™ technology. Zymeworks has entered into
separate agreements with BeiGene, Ltd. (BeiGene) and Jazz
Pharmaceuticals Ireland Limited (Jazz), granting each of
BeiGene and Jazz with exclusive rights to develop and commercialize
zanidatamab in different territories. Zanidatamab is currently
being evaluated in global Phase 1, Phase 2, and Phase 3 clinical
trials, including certain ongoing pivotal clinical trials as a
treatment for patients with HER2-expressing cancers. Zymeworks'
next clinical candidate, zanidatamab zovodotin (ZW49), is a
HER2-targeted bispecific antibody-drug conjugate (ADC) developed
using Zymeworks' proprietary Azymetric™ and ZymeLink™ Auristatin
technologies. Zanidatamab zovodotin is currently being evaluated in
a Phase 1 clinical trial for patients with a variety of
HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks
is also advancing a deep pipeline of product candidates based on
its experience and capabilities in both ADC and multispecific
antibodies (MSAT). In addition to Zymeworks' wholly owned pipeline,
its therapeutic platforms have been further leveraged through
strategic partnerships with global biopharmaceutical companies. For
information about Zymeworks, visit www.zymeworks.com and
follow @ZymeworksInc on Twitter.
Contacts:
Investor & Media Inquiries:
Diana PapoveDirector, Corporate Communications(604)
678-1388ir@zymeworks.com media@zymeworks.com
Zymeworks (NASDAQ:ZYME)
過去 株価チャート
から 4 2024 まで 5 2024
Zymeworks (NASDAQ:ZYME)
過去 株価チャート
から 5 2023 まで 5 2024